Evidence for cytochrome P4501A2-mediated protein covalent binding of thiabendazole and for its passive intestinal transport: Use of human and rabbit derived cells

Chemico-Biological Interactions

Volumn 127, Issue 2, 2000, Pages 109-124

  Coulet, Myriam ^a   Eeckhoutte, Claudine ^a   Larrieu, Gilberte ^a   Sutra, Jean François ^a   Alvinerie, Michel ^a   MacÉ, Katherine ^b   Pfeifer, Andrea ^b   Zucco, Flavia ^c   Laura Stammati, Anna ^d   De Angelis, Isabella ^d   Vignoli, Anna Lidia ^d   Galtier, Pierre ^a  

^a CEMAGREF   (France)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

^c CNR   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Covalent binding; Cytochrome P450; In vitro models; Intestinal transport; Thiabendazole

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BETA NAPHTHOFLAVONE; CLOFIBRATE; FUNGICIDE; PHENACETIN O DEETHYLASE; PHENOBARBITAL; RIFAMPICIN; TIABENDAZOLE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; COVALENT BOND; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; LIVER CELL; NONHUMAN; PASSIVE TRANSPORT; RABBIT;

ANIMALS; ANTINEMATODAL AGENTS; BIOLOGICAL TRANSPORT; BRONCHI; CACO-2 CELLS; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; CYTOCHROME P-450 CYP1A2; ENZYME INDUCTION; EPITHELIAL CELLS; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; ISOENZYMES; LIVER; MALE; PROTEIN BINDING; PROTEINS; RABBITS; THIABENDAZOLE;

ORYCTOLAGUS CUNICULUS;

EID: 0034600763     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(00)00167-8     Document Type: Article

References (39)

1. Brown H.D., Matzuk A.R., Ilves I.R.K. et al. Antiparasitic drugs. IV. 2-(4′-thiazolyl)benzimidazole, a new anthelminthic. J. Am. Soc. 83:1961;1764.
2. Hennekeuser H.H., Pabst K., Poeplau W., Gerok W. Thiabendazole for the treatment of trichinosis in humans. Texas Rep. Biol. Med. 27(Suppl. 2):1969;581-596.
3. Szeto S.Y., Joshi V., Price P.M., Holley J. Persistence and efficacy of thiabendazole on potatoes for control of silver scurf. J. Agric. Food Chem. 41:1993;2156-2159.
4. Arenas R.V., Johnson N.A. Liquid chromatographic fluorescence method for the determination of thiabendazole residues in green bananas and banana pulp. J. AOAC Int. 77:1994;710-713.
5. Ogata A., Ando H., Kubo Y., Hiraga K Teratogenicity of thiabendazole in ICR mice. Food Chem. Toxicol. 22:1984;509-520.
6. Mizutani T., Ito K., Nomura H., Nakanishi K. Nephrotoxicity of thiabendazole in mice depleted of glutathione by treatment with DL-buthionine sulphoximine. Food Chem. Toxicol. 28:1990;169-177.
7. Mizutani T., Yoshida K., Ito K. Nephrotoxicity of thiazoles structurally related to thiabendazole in mice depleted of glutathione by treatment with buthionine sulfoximine. Res. Commun. Chem. Pathol. Pharmacol. 75:1992;29-38.
8. Mizutani T., Yoshida K., Kawazoe S. Possible role of thioformamide as a proximate toxicant in the nephrotoxicity of thiabendazole and related thiazoles inglutathione-depleted mice: structure-toxicity and metabolic studies. Chem. Res. Toxicol. 6:1993;174-179.
9. Yoneyama M., Ichikawa H. Irreversible in vivo and in vitro binding of thiabendazole to tissue proteins of pregnant mice. Food Chem. Toxicol. 24:1986;1283-1286.
10. Nelson S.D. Metabolic activation and drug toxicity. I. Correlation of changes in covalent binding of reactivity metabolites with changes in the incidence and severity of toxicity. J. Med. Chem. 25:1982;753-765.
11. Tocco D.J. The metabolic fate of thiabendazole in sheep. J. Med. Chem. 7:1964;399-405.
12. Tocco D.J., Egerton J.R., Bowers W., Christensen V.W., Rosenblum C. Absorption, metabolism and elimination of thiabendazole in farm animals and a method for its estimation in biological materials. J. Pharmacol. Exp. Ther. 149:1965;263-271.
13. Tocco D.J., Rosenblum C., Martin C.M., Robinson H.J. Absorption, metabolism, and excretion of thiabendazole in man and laboratory animals. Toxicol. Appl. Pharmacol. 9:1966;31-39.
14. Coulet M., Dacasto M., Eeckhoutte C. et al. Identification of human and rabbit cytochromes P4501A2 as major isoforms involved in thiabendazole 5-hydroxylation. Fundam. Clin. Pharmacol. 12:1998;225-235.
15. Coulet M., Eeckhoutte C., Larrieu G. et al. Comparative metabolism of thiabendazole in cultured hepatocytes from rats, rabbits, calves, pigs and sheep, including the formation of protein-bound residues. J. Agric. Food Chem. 46:1998;742-748.
16. Hidalgo J.J., Raub T.J., Borchardt R.T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 96:1989;736-749.
17. Daujat M., Pichard L., Dalet C. Expression of five forms of microsomal cytochrome P450 in primary cultures of rabbit hepatocytes treated with various classes of inducers. Biochem. Pharmacol. 36:1987;3597-3606.
18. Van der Hoeven T., Coon M.J. Preparation and properties of partially purified cytochrome P450 and reduced nicotinamide adenine dinucleotide phosphatase cytochrome P450 reductase from rabbit liver microsomes. J. Biol. Chem. 249:1974;6202-6210.
19. Smith P.K., Krohn R.I., Hermason G.T. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
20. Macé K., Aguilar F., Wang J.S. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis. 18:1997;1291-1297.
21. Barcelo S., Macé K., Pfeifer A.M.A., Chipman J.K. Production of DNA strand breaks by N-nitrosodimethylamine and 2-amino-3-methylimidazo[4,5-f] quinoline in THLE cells expressing human CYP isoenzymes and inhibition by sulforaphane. Mutat. Res. 402:1998;111-120.
22. Macé K., Gonzalez F.J., Mcconell I.R. Activation of promutagens in a human bronchial epithelial cell line stably expressing human cytochrome P450 1A2. Mol. Carcinogen. 11:1994;65-73.
23. Pfeifer A.M.A., Macé K., Tromvoukis Y., Lipsky M.M. Highly efficient establisment of immortalized cells from adult human liver. Meth. Cell Science. 17:1995;83-89.
24. Lechner J.F., La Veck M.A. A serum-free method for culturing normal human bronchial epithelial cells at clonal density. J. Tissue Cult. Meth. 9:1985;43-48.
25. De Angelis I., Hoogenboom L.A.P., Huveneers-Oorsprong M.B.M., Zucco F., Stammati A. Established cell lines for safety assessment of food contaminants: differing furazolidone toxicity to V79, Hep 2 and Caco-2 cells. Food Chem. Toxicol. 32:1994;481-488.
26. Hoogenboom L.A.P., Van Kammen M., Berghmans M.C.J., Koeman J.H., Kuiper H.A. The use of pig hepatocytes to study the nature of protein bound metabolites of furazolidone: a new analytical method for their detection. Food Chem. Toxicol. 28:1991;321-328.
27. Ranaldi G., Islam K., Sambuy Y. Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob. Ag. Chemother. 36:1992;1374-1381.
28. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
29. Rey-Grobellet X., Eeckhoutte C., Sutra J.F., Alvinerie M., Galtier P. Major involvement of rabbit liver cytochrome P4501A in thiabendazole 5-hydroxylation. Xenobiotica. 26:1996;765-778.
30. Miller J.A. Carcinogenesis by chemicals: An overview. Cancer Res. 30:1970;559-576.
31. Bartolone J.B., Beierschmitt W.P., Birge R.B. et al. Selective acetaminophen metabolite binding to hepatic and extrahepatic proteins: an in vivo and in vitro analysis. Toxicol. Appl. Pharmacol. 99:1989;240-249.
32. Davidson R.N., Weir W.R., Kaye G.L., McIntyre N. Intrahepatic cholestasis after thiabendazole. Trans. R. Soc. Trop. Med. Hyg. 82:1988;620.
33. Roy M.A., Nugent F.W., Aretz H.T. Micronodular cirrhosis after thiabendazole. Dig. Dis. Sci. 34:1989;938-941.
34. Mizutani T., Suzuki K., Murakami M., Yoshida K., Nakanishi K. Nephrotoxicity of thioformamide, a proximate toxicant of nephrotoxic thiazoles, in mice depleted of glutathione. Res. Commun. Mol. Pathol. Pharmacol. 94:1996;89-101.
35. Delatour P., Parish R. Benzimidazole anthelmintics and related compounds: toxicity and evaluation of residues. Rico A.G. Drug Residues in Animals. 1986;175-203 Academic Press, New York.
36. Boulenc X., Bourrie M., Fabre I. Regulation of cytochrome P450 1A1 gene expression in a human intestinal cell line Caco-2. J. Pharmacol. Exper. Therap. 263:1992;1471-1478.
37. Carrière V., Lesuffleur T., Barbat A. Expression of cytochrome P450 3A in HT29-MTX cells and Caco-2 clone TC7. FEBS Lett. 355:1994;247-250.
38. Prueksaritanont T., Gorham L.M., Hochman J.H., Tran L.O., Vyas K.P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab. Dispos. 24:1996;634-642.
39. Crespi C.L., Penman B.W., Hu M. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P450 3A4. Pharm. Res. 13:1996;1635-1641.